Literature DB >> 18459542

Epidemiological, clinical and viral determinants of the increased prevalence of high-risk human papillomavirus (HPV) infections in elderly women.

K Syrjänen1, S M Kulmala, I Shabalova, N Petrovichev, V Kozachenko, T Zakharova, J Pajanidi, J Podistov, G Chemeris, L Sozaeva, E Lipova, I Tsidaeva, O Ivanchenko, A Pshepurko, S Zakharenko, R Nerovjna, L Kljukina, O Erokhina, M Branovskaja, M Nikitina, V Grunjberga, A Grunjberg, A Juschenko, R Santopietro, M Cintorino, P Tosi, S Syrjänen.   

Abstract

BACKGROUND: Population-based studies have reported a second peak of human papillomavirus (HPV) prevalence among women > 55 years, but reasons for this U-shaped HPV prevalence curve are poorly understood.
OBJECTIVES: To analyse determinants of high-risk HPV (HR-HPV) infections among postmenopausal women. STUDY DESIGN AND METHODS: A cohort of 3,187 women was stratified into three age categories: i) youngest age group < 25 years (n = 1.103); ii) women between 26-55 years (n = 2.004), and iii) women > 55 years (n = 80), analysed for epidemiological, clinical and virological determinants of their HR-HPV infections. Real-time PCR was used for HPV genotyping, analysis of viral loads for HPV16, 18/45, 31, 33/52/58, 35 and 39, and load of integrated HPV16.
RESULTS: Age-standardised prevalence of HR-HPV infections showed a second peak among women > 55 years, with a perfect U-shaped curve (R2 = 0.966). The factors explaining this increased HR-HPV prevalence among older women include: i) cohort effect, ii) higher viral loads for HR-HPV types with cubic model curve (R2 = 0.714) for HPV 16, iii) distinct shift (p = 0.0001) from multiple-type infections to single HR-HPV types, iv) transition from episomal to integrated HPV16 (p = 0.009), v) higher load of integrated HPV16 (p = 0.009), and, vi) higher proportion of incident infections, higher rate of viral persistence, and lower rate of HR-HPV clearance.
CONCLUSIONS: These data suggest that in women who fail to eradicate their HR-HPV infection until menopause, selection of integrated viral clone has taken place, driving the process towards progressing disease. Consequent to this, most of the HR-HPV infections in women > 55 years were associated with high-grade CIN or invasive carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18459542

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  6 in total

1.  Behavioral/lifestyle and immunologic factors associated with HPV infection among women older than 45 years.

Authors:  Paula González; Allan Hildesheim; Ana Cecilia Rodríguez; Mark Schiffman; Carolina Porras; Sholom Wacholder; Alfonso García Piñeres; Ligia A Pinto; Robert D Burk; Rolando Herrero
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10-15       Impact factor: 4.254

2.  Proposal for a descriptive and differentiated presentation of the longitudinal impact of the new organized cancer screening guideline and HPV vaccination in Germany.

Authors:  F Neis; B Holleczek; M Henes; I Juhasz-Böss; D Wallwiener; K J Neis
Journal:  Arch Gynecol Obstet       Date:  2022-09-02       Impact factor: 2.493

3.  Human papillomavirus persistence in young unscreened women, a prospective cohort study.

Authors:  Channa E Schmeink; Willem J G Melchers; Albertus G Siebers; Wim G V Quint; Leon F A G Massuger; Ruud L M Bekkers
Journal:  PLoS One       Date:  2011-11-23       Impact factor: 3.240

4.  HPV-based screening for cervical cancer among women 55-59 years of age.

Authors:  Lovisa Bergengren; Gabriella Lillsunde-Larsson; Gisela Helenius; Mats G Karlsson
Journal:  PLoS One       Date:  2019-06-14       Impact factor: 3.240

5.  Analysis of influencing factors of viral load in patients with high-risk human papillomavirus.

Authors:  Xuerong Lu; Tiantian Wang; Youzhong Zhang; Yuzhen Liu
Journal:  Virol J       Date:  2021-01-06       Impact factor: 4.099

6.  Value of high-risk human papillomavirus 16 deoxyribonucleic acid testing with cytological entities in peri and postmenopausal women.

Authors:  Veena Kashyap; Suresh Hedau
Journal:  J Cytol       Date:  2013-07       Impact factor: 1.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.